申请人:AVENTIS PHARMA LTD
公开号:WO2001047922A2
公开(公告)日:2001-07-05
The invention is directed to compositions containing physiologically active compounds of general formula (I) wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8,-C(=O)-NY3Y4,-CO2R?8,-NY3Y4,-N(R6¿)-C(=O)-R?7, -N(R6¿)-C(=O)-NY?3Y4,-N(R6¿)-C(=O)-OR?7, -N(R6)-SO¿2-R?7,-N(R6)-SO¿2-NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C(=O)-OR5 or -C(=O)-NY3Y; and X1 represents N, CH, C-halo, C-CN, C-R?7, C-NY3Y4¿, C-OH, C-Z2R7, C-C(=O)-OR5, C-C(=O)-NY?3Y4, C-N(R8¿)-C(=O)-R7, C-SO¿2?-NY?3Y4, C-N(R8)-SO¿2-R7, C-alkenyl, C-alkynyl or C-NO¿2?; and their produgs, and pharmaceutically acceptable salts and solvates of such compounds and their produgs, as well as to novel compounds within the scope of fomula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.